Sepsis Clinical Trial
Official title:
Rates of Sarcopenia Development Using Abdominal CT Imaging in the Critically Ill With Sepsis Compared to the Critically Ill With Trauma
Using abdominal computed tomography (CT) imaging, the investigators will estimate total body
muscle mass at two time points in Intensive Care Unit (ICU) by assessing cross-sectional
muscle areas at the L3 vertebral body level. This allows for a determination of the rate of
sarcopenia development in the ICU.
With this information, the investigators propose to test if the rates of the development of
sarcopenia differ in critically ill subjects with sepsis compared to a reference group of
critically ill subjects with trauma (without sepsis).
The investigators propose to compare rates of development of sarcopenia in critically ill,
septic subjects with a reference cohort of critically ill, trauma subjects who are not
septic. The null hypothesis is that the rates of muscle loss in subjects with sepsis (a
condition associated with high levels of inflammation) are comparable with the rates of
muscle loss in subjects without sepsis. As secondary outcomes, the investigators will
evaluate whether rates of muscle loss correlate with clinical assessments in the ICU (body
mass index, frailty score, illness severity score), with clinical course through the hospital
(ICU length of stay (LOS), duration of mechanical ventilation, hospital LOS, ICU
readmissions, hospital readmissions), and with outcomes (discharge destination, ICU
mortality, hospital mortality and six-month mortality).
To answer this question, the investigators propose to retrospectively analyze existing
abdominal CT imaging of subjects treated in the ICU. Muscle mass estimations will be
performed by determining skeletal muscle cross-sectional area for muscles at the level of the
L3 vertebra using previously validated techniques. The CT images will have been gathered as
part of routine care for subjects admitted to a mixed medical-surgical ICU. These data will
be correlated with anonymized clinical and demographic information. Study participants will
be grouped into two cohorts - subjects admitted to the ICU for sepsis, and subjects admitted
to the ICU for trauma. People who experience both trauma and sepsis will be excluded. Only
subjects with at least 2 or more abdominal CT imaging event will be included.
Results from this study will be assessed using a generalized linear model to determine if the
two groups are different. From earlier studies, the investigators estimate that 73 subjects
will be required in each group to detect between-group differences for the primary outcome.
The results of this study will add to the general understanding of the rates of muscle loss
in a critical care setting for subjects admitted to ICU with sepsis, as compared to subjects
with trauma. Secondary outcome information will be presented descriptively to show sarcopenia
rates for the two cohorts, in the context of select clinical, demographic and administrative
variables.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |